- Home
- WALD vs CBIO Comparison
WALD vs CBIO Comparison
Compare WALD & CBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WALD
- CBIO
- Stock Information
- Founded
- WALD 1988
- CBIO 2003
- Country
- WALD United States
- CBIO United States
- Employees
- WALD N/A
- CBIO N/A
- Industry
- WALD Package Goods/Cosmetics
- CBIO
- Sector
- WALD Consumer Discretionary
- CBIO
- Exchange
- WALD Nasdaq
- CBIO Nasdaq
- Market Cap
- WALD 306.3M
- CBIO 308.0M
- IPO Year
- WALD 2021
- CBIO N/A
- Fundamental
- Price
- WALD $1.56
- CBIO $14.29
- Analyst Decision
- WALD Strong Buy
- CBIO Strong Buy
- Analyst Count
- WALD 5
- CBIO 5
- Target Price
- WALD $4.96
- CBIO $25.60
- AVG Volume (30 Days)
- WALD 528.0K
- CBIO 98.3K
- Earning Date
- WALD 11-11-2025
- CBIO 07-31-2025
- Dividend Yield
- WALD N/A
- CBIO N/A
- EPS Growth
- WALD N/A
- CBIO N/A
- EPS
- WALD N/A
- CBIO N/A
- Revenue
- WALD $273,868,000.00
- CBIO N/A
- Revenue This Year
- WALD $10.37
- CBIO N/A
- Revenue Next Year
- WALD $14.37
- CBIO N/A
- P/E Ratio
- WALD N/A
- CBIO N/A
- Revenue Growth
- WALD 25.55
- CBIO N/A
- 52 Week Low
- WALD $1.50
- CBIO $10.83
- 52 Week High
- WALD $4.40
- CBIO $21.40
- Technical
- Relative Strength Index (RSI)
- WALD 35.98
- CBIO 52.92
- Support Level
- WALD $1.50
- CBIO $13.50
- Resistance Level
- WALD $1.79
- CBIO $16.00
- Average True Range (ATR)
- WALD 0.16
- CBIO 0.79
- MACD
- WALD 0.00
- CBIO 0.16
- Stochastic Oscillator
- WALD 10.00
- CBIO 39.68
About WALD Waldencast plc
Waldencast PLC is a beauty and wellness operating platform. The company is organized into two reportable segments namely Obagi Skincare and Milk Makeup. The company generates the majority of its revenue from the Obagi Medical segment. The Obagi Medical segment is engaged in developing, marketing, and selling skin health products. The Milk Makeup segment includes developing, marketing, and selling cosmetics, skincare, and other beauty products. Geographically the company generates the majority of its revenue from North America region.
About CBIO Crescent Biopharma Inc. Common Stock
Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent believes CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. Crescent is advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.